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Economics, Warsaw, PolandA B S T R A C TObjectives: We aimed to compare the use of cost-effectiveness analysis
and cost-utility analysis in health technology assessment in Poland.
Methods: We analyzed all the submissions (155) made to the Polish
Agency for Health Technology Assessment in the period 2007 to 2011,
with 316 intervention-comparator comparisons reporting incremental
cost-effectiveness ratios (ICERs) or incremental cost-utility ratios
(ICURs). We compared ICERs and ICURs when both were reported
(31%), determined factors associated with reporting one or the other,
and tested the precision of their assessment. Results: In 13% of the
cases, ICER and ICUR led to different decisions (were on opposite sides of
the willingness-to-pay threshold). Cost-effectiveness analyses were
more frequently performed in oncology, offering at the same time more
favorable results. It was also more frequent for longer time-horizon
models, although then ICER values were on average higher. Conclusions:ee front matter Copyright & 2014, International S
r Inc.
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ndence to: Michał Jakubczyk, Institute of EconomeIn Poland, cost-utility analysis is a usual approach of increasing popular-
ity. Interestingly, although assessing ICUR requires additional assump-
tions, it is estimated more precisely (reported ranges of values in
sensitivity analyses are narrower), especially in oncology. ICER and ICUR
disagree more often than previously shown in literature. There seem to
be no clear signs of biases in submissions (selecting whether to present
ICER or ICUR on the basis of their values), but the current study is limited
because only the values presented by manufacturers in the submission
are available.
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Health technology assessment (HTA) reports presenting the
rationale to reimburse a new health technology typically encom-
pass an economic analysis, that is, quantiﬁcation of additional
cost of using this technology in relation to additional health
effects [1,2]. Health effects are usually measured as life-years
gained (LYGs) or quality-adjusted life-years (QALYs), accounting
also for the quality-of-life outcomes [3]. An economic analysis in
which LYGs are used is often referred to as cost-effectiveness
analysis (CEA) with its parameter of interest being called incre-
mental cost-effectiveness ratio (ICER), whereas an analysis in
which QALYs are used is often called cost-utility analysis (CUA)
and the resulting parameter is called incremental cost-utility
ratio (ICUR). The terms ICER and ICUR are sometimes not
distinguished and the context tells whether the result is
expressed in LYGs or QALYs. The ICER/ICUR is then compared
with the (ofﬁcial or approximate) willingness to pay (WTP) for a
unit of effect, that is, threshold to make a ﬁnal recommendation.
Because HTA aims to evaluate the complete economic and
clinical consequences, it would seem natural to favor CUA overCEA. Indeed, although national HTA guidelines differ and may be
sometimes vague (cf. Table 1), CUA is overall preferred (strongly
preferred in six countries, somewhat preferred in two, not
preferred in ﬁve). Agency for Health Technology Assessment in
Poland (AHTAPol) guidelines treat CEA and CUA equally,
demanding that the choice between them be justiﬁed; however,
the Polish Reimbursement Act, which came into force in 2012,
strictly prefers CUA.
This article aims to compare the use of CEA and CUA in HTA in
Poland via econometric analysis of data in submissions. In partic-
ular, we intend to analyze 1) what leads to the selection of CEA or
CUA; 2) how their results differ (point values and range in sensitivity
analysis); and 3) whether any bias is present, that is, preferring a
more favorable type of analysis to present in a submission.
Our analysis can help to answer the question whether such
regulations, obliging manufacturers to present CUAs, were
needed in Poland (e.g., when there seems to have been some
bias in selecting CEA or CUA) and how they can affect the natural
path of HTA development. Such analysis may support other
countries in the Central and Eastern European region in shaping
their formal HTA regulations.ociety for Pharmacoeconomics and Outcomes Research (ISPOR).
o conﬂicts of interest with regard to the content of this article.
trics, Warsaw School of Economics, al. Niepodległości 162, 02-554
Table 1 – Summary of selected national guidelines for the form of economic evaluation.
Country, institution; guidelines, year Recommendations for the analytic method in economic evaluation CUA preferred over CEA?
Australia, Pharmaceutical Beneﬁts Advisory Committee;
Guidelines for Preparing Submissions to the Pharmaceutical
Beneﬁts Advisory Committee, 2008 [4]
“Cost-utility analysis (generally preferred). (…), a cost-utility analysis is the
preferred form of economic evaluation for either or both of the following
situations:
- where there is a claim of incremental life-years gained in the economic
evaluation - in order to assess the impact of quality adjusting that survival gain
- where relevant direct randomised trials report results using a MAUI.”
Yes, CUA generally preferred.
Belgium, Belgian Health Care Knowledge Centre; Belgian
Guidelines for Economic Evaluations and Budget Impact
Analyses: Second Edition, 2012 [5]
“Cost-effectiveness analysis should be used if improving life expectancy is the
main objective of the treatment (…). Cost-utility analysis should be used if
the treatment has an impact on health-related quality of life that is
signiﬁcant to the patient or if there are multiple patient-relevant clinical
outcome parameters expressed in different units. If a cost-utility ratio is
presented as a reference case analysis result, the corresponding cost per life-
year gained should also be presented.”
No. CUA preferred if the treatment
has an impact on HRQOL. Should be
accompanied by CEA.
Canada, Canadian Agency for Drugs and Technologies in Health;
Guidelines for the Economic Evaluation of Health
Technologies, 2006 [6]
“A CUA should be used in the Reference Case where meaningful HRQL
differences between the intervention and alternatives have been
demonstrated, and where appropriate preference (utility) data are available.
A CEA should be used as the Reference Case when a CUA is an inappropriate
choice. Use a ﬁnal outcome (e.g., life-years gained), or if that is impossible, an
important patient outcome. (…)”
Qualiﬁed yes.
France, Collège des Économistes de la Santé; French Guidelines
for the Economic Evaluation of Heath Care Technologies, 2004
[7]
“Each evaluation has its own particular scope and limitations. The type of
study selected should be clearly stated and justiﬁed with respect to the issue
addressed, and must be described at the start of the study. The author
should also provide his personal deﬁnition of the type of study used.”
No, it depends on the case.
Finland, Ministry of Social Affairs and Health; Guidelines for
Preparing a Health Economic Evaluation, 2009 [8]
“The choice of the method of analysis most suitable for each situation (cost-
minimization analysis, cost-effectiveness analysis, cost-utility analysis and
cost-beneﬁt analysis) depends primarily on how the therapies compared
affect patients’ health state.”
No, it depends on the case.
Ireland, The Health Information and Quality Authority;
Guidelines for the Economic Evaluation of Heath Technologies
in Ireland, 2010 [9]
“The preferred evaluation type for the reference case is a cost-utility analysis
(CUA) with the outcomes expressed in terms of quality-adjusted life-years
(QALYs). In exceptional circumstances, a cost-effectiveness analysis (CEA)
with the outcomes expressed in terms of life-years gained (or other relevant
outcome if the technology does not add life-years) may be used as the
reference case when a cost-utility analysis is an unsuitable choice. Clear,
detailed empirical evidence must be provided to justify this position.”
Yes.
The Netherlands, College voor zorgverzekeringen; Guidelines for
Pharmacoeconomic Research, 2006 [10]
“If the improvement in quality of life forms an important effect of the drug
being assessed, then it is necessary to carry out a cost-utility analysis
(CUA). If this is not the case, then a cost-effectiveness (CEA) has to be
carried out. (…)”
No, it depends on the case.
New Zealand, Pharmaceutical Management Agency (PHARMAC);
Guidelines for Funding Applications to PHARMAC, 2010 [11]
“Economic analyses should be in the form of a CUA, with beneﬁts measured in
terms of quality-adjusted life-years (QALYs). In cases where the clinical
outcomes of the drug and the comparator have been shown to be equivalent,
a cost-minimisation analysis may be appropriate. Other forms of cost-
effectiveness or cost-beneﬁt analyses (CBA) should not be provided to
PHARMAC.”
Yes.
continued on next page
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Poland, Polish Agency for Heath Technology Assessment;
Guidelines for Conducting Health Technology Assessment,
2009 [12]
“Analytical method is always selected according to health effects identiﬁed and
measured and the choice should always be justiﬁed. A standard economic
analysis as part of a HTA report should be composed of:
- cost-consequences analysis,
- cost-effectiveness analysis or cost-utility analysis; if there are no differences in
clinical effectiveness between health technologies compared the cost-
effectiveness analysis may be replaced with cost minimisation analysis. The
choice of one method does not exclude using another one as an additional
analysis, if the author ﬁnds it justiﬁed.”
No, it depends on the case.
Scotland, Scottish Medicines Consortium; Guidance to
Manufacturers for Completion of New Product Assessment
Form, 2013 [13]
“In general, cost-utility analysis is the preferred form of economic evaluation,
with health effects expressed in terms of quality-adjusted life-years
(QALYs).”
Yes.
Spain; Spanish Recommendations on Economic Evaluation of
Health Technologies, 2010 [14]
“Develop a cost-effectiveness analysis when there is a clinically signiﬁcant
effect (improvement in health) and sufﬁcient information is not available to
perform a cost-utility analysis.”
Qualiﬁed yes. CEA should be
performed when CUA-needed data
are lacking.
Sweden, The Pharmaceutical Beneﬁts Board; General Guidelines
for Economic Evaluations from the Pharmaceutical Beneﬁts
Board, 2003 [15]
“Cost-effectiveness analysis is recommended, with quality-adjusted life-years
(QALYs) as the measure of effect. In treatments that mostly affect survival,
both QALYs and gained life-years should be shown (…). If it is difﬁcult to use
QALYs (e.g. with heavy pain over a short time in connection with treatment),
then a cost-beneﬁt analysis with the willingness to pay may be used as a
measure of effect.”
Yes.
United Kingdom, National Institute for Health and Care
Excellence; Guide to the Methods of Technology Appraisal,
2013 [16]
“For the reference case, cost-effectiveness (speciﬁcally cost–utility) analysis is
the preferred form of economic evaluation. This seeks to establish whether
differences in costs between options can be justiﬁed in terms of changes in
health effects. Health effects should be expressed in terms of QALYs.”
Yes.
HRQOL, health-related quality of life; HTA, health technology assessment.
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V A L U E I N H E A L T H R E G I O N A L I S S U E S 4 C ( 2 0 1 4 ) 6 6 – 7 4 69A similar analysis was undertaken by Chapman et al. [17],
who compared published results of CEA/CUA. They compared 173
ICER/ICUR pairs (from 63 articles in the CUA database at the
Harvard Center for Risk Analysis) published before 1998 to
investigate the effect of including health-related quality of life
(HRQOL) in the analysis. They concluded that the two approaches
differ only slightly and usually lead to the same decision.
Research by Tengs [18] and Greenberg and Neumann [19] con-
ﬁrmed these results for oncological interventions, showing a
tendency for ICURs to be higher than ICERs (in approximately
two-thirds of the situations).Methods
We follow the general methodology of Chapman et al. [17],
applying it to a data set consisting of all manufacturers’ sub-
missions to the AHTAPol in the period 2007 to 2011. Therefore,
the data set is more recent and homogenous—it relates to a
single country and currency and more or less single WTP thresh-
old (possibly increasing over time). The data set includes sub-
missions reporting CUA, CEA, and both, thus enabling detection
of the determinants that affect the choice of one form of the
analysis and not the other. The use of submissions data reduces
the risk of publication bias evident in published articles. In 2012,
the Reimbursement Act changed policy to preference for CUA
where possible; before this, the analysis reﬂected the choice of
the analyst. Thus, the use of submissions is less regulation-
dependent and more transferable to other countries.
Our analysis consists of three parts. First, we compare ICERs
and ICURs in reports that include both of them. We quantify the
difference between the two and determine how often adjusting
for HRQOL affects the decision about allocating resources. Sec-
ond, we analyze all the data collected and try to determine the
factors that inﬂuence the choice of ICER or ICUR. Finally, we
analyze the differences in estimation precision for ICERs and
ICURs to verify whether the precision of ICURs is lower than that
of ICERs (under the premise that the quality adjustment added to
the calculation process may intuitively increase the uncertainty)
and to identify the factors that are associated with the uncer-
tainty of estimation.
Data Sources
We searched through all 201 economic analyses submitted by
drug manufacturers to AHTAPol in the period 2007 to 2011. Our
inclusion criteria were as follows: 1) CEA or CUA with outcome
measured in LYG or QALY (i.e., we excluded cost-minimization
analyses and analyses with effects expressed in natural health
outcomes); 2) costs measured in Polish zloty (PLN); and 3)
conducted sensitivity analysis (e.g., one-way, multiway, and
probabilistic). The last criterion resulted in removing two reports
only. We included analyses that reported multiple ratios because
of more than one comparator or intervention. In such cases, we
treated each single comparison as a separate data record. We did
not select reports on the basis of their quality. Our goal was to
assess the status quo among all the analyses submitted to
AHTAPol.
We included 155 reports and 316 intervention-comparator
comparisons, with 14 presenting ICER only, 204 ICUR only, and
the remaining 98 both. Thus, ICER and ICUR were presented in
35% and 96% of comparisons, respectively.
We extracted the maximum and minimum value of ICER/ICUR
from the sensitivity analysis, the year when submission was
prepared, time horizon of the model (assumed 99 years in lifelong
models), and disease information (a binary variable: 1—interven-
tion used in oncology; 0—all other interventions). We did notexplicitly account for the comparator (e.g., do nothing or active
treatment) because we concentrated on detecting when CEA/CUA
is selected and not on the absolute levels of ICER/ICUR.
We did not include information on the drug manufacturer (55
different companies) or the company preparing the report (14
different commercial or academic entities). We decided not to use
them because in our opinion that would require introducing too
many dummy variables and make the estimation technically
impossible or result in possible spurious conclusions because of
multiple hypotheses testing.
The selection of variables was inﬂuenced by Chapman et al.
[17] and Devlin and Parkin [20]. Instead of interpreting whether
the condition or intervention is acute or chronic, however, we
decided to collect information about the time horizon of the
model, which seems to be more objective and analysis-oriented.
We also decided to put special emphasis on oncology because
most treatments for cancer are generally expensive and associ-
ated with relatively short survival as well as HRQOL.
Because some of the ICER/ICUR values were very large, owing
to technical reasons, we introduced the upper limit of 10 million
PLN (set arbitrarily, much above the perceived WTP of around
100,000 PLN at that time, €1 E 4.1 PLN). We assumed that a
dominated technology has ICER/ICUR (the type of analysis—CEA
or CUA—was declared in the report) equal to this upper cap—that
is, much above the threshold and in effect not recommended for
any WTP. Thanks to this substitution, the dominated technology
has got a numerical value assigned to it and it is at least as large
as any ratio value in the data set. Analogously, a dominant
technology has ICER/ICUR equal to 0 (i.e., recommended for any
WTP). There were no situations (within our inclusion criteria) in
which positive ICER/ICUR resulted from a technology reducing
both cost and effects.
Statistical Methods
We used both parametric (Pearson) and nonparametric (Spear-
man) correlation coefﬁcients. Nonparametric tests were generally
used to compare distributions: the Wilcoxon test in the case of
paired data and the Mann-Whitney U test in the case of unpaired
data. We also present the results of parametric, paired t tests,
whenever this yields additional insight. Signiﬁcance level P* ¼ 0.05
was adopted for these comparisons. While building logistic
regression models, potential regressors were removed one by
one until all P values were o0.1 (we used a bit higher signiﬁcance
level so as to improve sensitivity in detecting determinants).
Because we aimed at identifying determinants and not making
forecasts, we used statistical signiﬁcance criterion and not model
ﬁt. We tried to include interaction terms for variables that were
themselves statistically signiﬁcant. Missing values were not
imputed and resulted in dropping observations. All the calcula-
tions were carried out with R 2.15.0.
Comparison of ICER and ICUR
In this part we restricted data to the subset that presented both
the ICER and the ICUR. We determined the frequency of the
difference between ratios being positive and negative and calcu-
lated the ICUR as a percentage of the ICER, that is, the relative
impact of life quality weighting. We compared the distributions
using the Mann-Whitney U test. We determined the number of
cases when the ICER and the ICUR lay on different sides of the
cost-effectiveness threshold of 100,000 PLN, thus leading to
different decisions (since 2012 this threshold is deﬁned by law
as triple annual gross domestic product per capita: 99,543 PLN as
of September 2012, increasing to 105,801 PLN at the beginning of
November 2012; before 2012, the threshold was informally per-
ceived to be between 80,000 and 110,000). Finally, we performed a
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Fig. 1 – Bagplot of ICERs and ICURs; points are drawn when
both are available (values in this graph, though not in
calculations, are further limited to 310,000 PLN to make it
more readable); “*” denotes the bivariate median; “▲”/“♦”
denote the pair of univariate medians for paired/all ratios;
“■”/“●” denote the pair of univariate means for paired/all
ratios; the gray bag contains 50% of all observations. ICER,
incremental cost-effectiveness ratio; ICUR, incremental cost-
utility ratio; PLN, Polish zloty.
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with the ICER/ICUR being more favorable. We included as explan-
atory variables the year the report was made, disease informa-
tion, and time horizon of the model.
Determinants for Reporting the ICER or the ICUR
To determine factors affecting the choice of the type of analysis,
we included all the comparisons, that is, the ICER and the ICUR
also reported individually. Because of the strong asymmetry in
the data (the ICUR not presented in only 4.4% of the cases and the
ICER in 64.6%), we focused on a model explaining the publication
of the ICER. We used logistic regression with a year of the
performance, disease information, and time horizon of the model
as potential regressors. We also used (as a potential regressor) the
binary variable denoting whether the ICUR was above or below
the WTP threshold (to check whether high evaluations of ICURs
led to more frequent ICER reporting). For the completeness of the
study, we built an analogous model for the ICUR; however, the
current data set hinders strong inferences.
We also included the precision of ICER/ICUR estimation to
detect whether, for example, poor precision of one leads to a
more frequent reporting of the other. We experimented with
three measures of an error. In each, the maximal and minimal
value of the ICER/ICUR (as presented in the report in any kind of
sensitivity analysis) was used. Equations 1 to 3 present three
deﬁnitions used for the ICER (analogous formulas were used for
the ICUR).
ICERerror1 ¼ atan ICERmax=100,000
 atan ICERmin=100,000
  ð1Þ
ICERerror2 ¼ ICERmaxICERminþ1ð Þ= ICERþ1ð Þ ð2Þ
ICERerror3 ¼ ICERmaxþ1ð Þ= ICERminþ1ð Þ ð3Þ
The ﬁrst was deﬁned as an angle in the cost-effectiveness
plane between the lines denoting the maximal and minimal
ICER/ICUR. The slope coefﬁcients were divided by 100,000 so as
the line of WTP was a 45-degree line halving the ﬁrst quadrant.
The second one relates the difference between minimal and
maximal value to the base-case value. The third one is a relative
measure of difference between minimal/maximal values. We
added 1s to denominators so as to avoid the division-by-zero
problem.
Precision of the Assessment of the ICER and the ICUR
First, we determined how often maximum and minimum (as
taken from sensitivity analysis) corresponding ratios were on
opposite sides of the WTP threshold. This is a crude indicator of
how precise both measures are, and a direct indicator of whether
this imprecision poses a problem to a decision maker. Second, we
tried to verify the intuition that including additional HRQOL
parameters usually worsens the precision of the estimates, and
so ICUR-related errors should be greater than ICER-related errors.
We investigated the three measures deﬁned above. We per-
formed a nonparametric Wilcoxon test to compare the precision
of assessment between ICERs and ICURs, when presented
together and separately. Last, we tried to identify factors asso-
ciated with differences in ICER/ICUR precision of estimation.Results
General Data Description
In 11 of 112 CEAs and in 36 of 302 CUAs, the intervention turned
out to be dominant and in case of 3 CUAs it was dominated. In
other cases, the intervention was more effective and costlier.Figure 1 presents the data in the form of a bagplot (including the
truncation value of 310,000 PLN for the sake of the graph being
readable) along with approximate threshold of 100,000 PLN and
45-degree line.
ICER and ICUR estimations are positively correlated with
Pearson linear correlation coefﬁcient of 0.5091 (P* o 0.0001) and
Spearman coefﬁcient of 0.9105 (P*o 0.0001). Usually, ICERs/ICURs
are below the threshold—the medians for all available values of
the ICER and the ICUR amount to 79,389 PLN/LYG and 66,886 PLN/
QALY, respectively (“♦”). Calculating the medians for paired
values only (“▲”) or calculating the bivariate median (“*”) does
not change the results qualitatively.
Mean ICERs/ICURs calculated when both were available equal
173,775 PLN/LYG and 130,606 PLN/QALY (“■”). Thus, the ICER is
greater on average. The majority of data points, however, lie
above the 45-degree line, meaning that usually, when both are
reported, the ICUR is greater (thus including HRQOL in the
analysis decreases the cost-effectiveness of the technology being
studied).
Calculating means for all (nontruncated) the data yields
185,606 PLN/LYG and 309,000 PLN/QALY (“●”). The increase in
both values means that both ratios are greater on average when
unaccompanied. The increase is much larger for the ICUR (and
also more reliable because of the larger number of cases when
the ICER is not reported).
Intuitively, there is a positive skew in the data for the ICER
and the ICUR (means larger than medians). Highest (noncapped)
ratios amount to 4,606,000 PLN/LYG and 17,430,000 PLN/QALY.
This suggests using nonparametric tests when comparing values
for both types of ratio (and capping). The ﬁrst quartiles amount to
24,060 PLN/LYG and 18,420 PLN/QALY, whereas third quartiles
amount to 164,500 PLN/LYG and 144,700 PLN/QALY.
Comparison of Paired Ratios
The previous section showed that ICERs and ICURs have similar
values—the difference between unpaired ICERs and ICURs is not
Table 2 – The ﬁnal logistic regression modeling
results for the ICER being greater than the ICUR (the
ICUR being more favorable for the technology).
Explanatory variable Estimate Odds P
Intercept 823.1925 NA 0.0790
Year of submission 0.4103 0.66 0.0786
Oncology (1 ¼ yes) 1.3401 0.26 0.0415
Time horizon (y) 0.0171 1.02 0.0229
ICER, incremental cost-effectiveness ratio; ICUR, incremental cost-
utility ratio; NA, not applicable/available.
V A L U E I N H E A L T H R E G I O N A L I S S U E S 4 C ( 2 0 1 4 ) 6 6 – 7 4 71statistically signiﬁcant (Mann-Whitney U test, P* ¼ 0.3512). Still,
the differences between the two, limited to comparisons when
both are reported, present some pattern. The ICER was greater
than the ICUR in only 28.5% of the cases (28 of 98) and smaller in
59.2% (58 of 98). In the remaining 12.2%, both were equal (to 0
because interventions were dominant). Therefore, usually includ-
ing HRQOL in the analysis reduces the additional effect of the
technology being evaluated. The paired nonparametric test
shows this qualitative difference to be statistically signiﬁcant
(Wilcoxon paired test, P* ¼ 0.0049).
The analysis of means yields a different picture. As men-
tioned above, the average ICER is greater by 43,169 PLN in cases in
which both the ICER and the ICUR are presented, though the
difference is not statistically signiﬁcant (t test, P* ¼ 0.3471).
Therefore, in the less frequent situations when including HRQOL
reduces the cost-effectiveness ratio, this reduction can be sub-
stantial. Chapman et al. [17] in their study obtained quite the
opposite (Cf. Discussion).
In 35% of the cases, quality of life adjusting changed the cost-
effectiveness ratio by less than 20% (i.e., the ICUR was within
20% bounds of the ICER), and in 70% of the cases by less than
40%. The maximal relative percentage difference amounted to
approximately 120%.
In 33 cases (34%) ICERs and in 38 cases (39%) ICURs were above
100,000 PLN, assumed approximately as the threshold value in
Poland. In 13 cases (13%), the two were on the opposite sides of
the threshold, and thus pointed to different resource allocation
decisions. In 4 cases, the ICUR was favorable (while the ICER was
unfavorable) and in 9 cases vice versa. This again somewhat
differs from Chapman’s et al. [17] study, in which 8.1% of the
cases were on the other side of the $50,000 threshold (and only
6.4% for the threshold equal to $100,000).separately paired
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Fig. 2 – Box plot of ICERs and ICURs when paired vs when pres
calculations, are further limited to 400,000 PLN to make it more
quartiles, and the whiskers denote min and max; the dot repre
ICUR, incremental cost-utility ratio; PLN, Polish zloty.Finally, we performed a logistic regression analysis to identify
determinants of ICER 4 ICUR (of introducing HRQOL positively
affecting the technology being assessed). In the ﬁnal model, we
retained three variables—the year of performance, time horizon
of the model, and whether the intervention was used for
oncology—that proved to be signiﬁcant (Table 2). All the remain-
ing variables and interaction terms between variables from
Table 2 were insigniﬁcant with P* 4 0.1.Determinants for Reporting ICERs or ICURs
Fig. 2 visualizes the distributions of ratios when reported
separately and paired (there are only 14 cases in which the
ICER was unaccompanied by the ICUR). The data suggest that
unpaired ICER is usually greater and this is conﬁrmed by a
nonparametric test (Mann-Whitney U test, P* o 0.0001). In the
case of the ICUR, the nonparametric approach yields no differ-
ence (P* ¼ 0.9293), although the parametric one does (t test,separately paired
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ented separately (values in this graph, though not in
readable); the line denotes the median, the box denotes
sents the mean. ICER, incremental cost-effectiveness ratio;
Table 3 – Logistic regression modeling results for
factors associated with ICER/ICUR reporting.
Explanatory variable Estimate Odds P
Determinants of the ICUR being published
Intercept 2043.6523 NA 0.0004
Year of submission 1.0193 2.77 0.0004
Oncology 1.7927 0.17 0.0027
Determinants of the ICUR being published (alternative model)
Intercept 2679.4330 NA 0.0007
Year of submission 1.3359 3.80 0.0007
Is the ICER4100,000? 2.9656 0.52 0.0013
Determinants of the ICER being published
Intercept 1.8159 NA o0.0001
Time horizon (y) 0.0144 1.01 o0.0001
Oncology 2.4113 11.14 o0.0001
ICER, incremental cost-effectiveness ratio; ICUR, incremental cost-
utility ratio; NA, not applicable/available.
Table 4 – Logistic regression modeling including
precision of estimation as explanatory variables.
Explanatory variable Estimate Odds P
Determinants of the ICUR being published
Intercept 1805 NA 0.0319
Year of submission 0.8985 2.46 0.032
Time horizon (y) 0.024 0.98 0.0889
ICER error 1 0.0823 1.09 0.0023
Determinants of the ICER being published
Intercept 1.735 NA o0.0001
Time horizon (y) 0.014 1.01 0.0004
Oncology 2.534 12.60 o0.0001
ICUR error 3 0.0002 0.99 0.0081
ICER, incremental cost-effectiveness ratio; ICUR, incremental cost-
utility ratio; NA, not applicable/available.
Table 5 – Logistic regression modeling results
comparing the precision of CEA and CUA.
Explanatory variable Estimate Odds P
Determinants of the ICUR error 4 the ICER error
Intercept 1184.6765 NA 0.0418
Year of submission 0.5902 0.55 0.0417
Oncology 1.7383 0.18 0.0445
CEA, cost-effectiveness analysis; CUA, cost-utility analysis; NA,
not applicable/available.
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strong asymmetry, the nonparametric result seems to be more
reliable.
We performed the logistic regression analysis to determine
factors associated with the reporting of the ICUR. We found two,
non-nested models interesting (Table 3). In the ﬁrst one, present-
ing the ICUR was explained by the year of submission (reporting
increasing in time) and oncology (less frequent reporting in
oncology—as explained previously, in oncology ICURs are less
favorable than ICERs). In the second model, we introduced a
binary variable representing the ICER value being above the WTP
threshold (then the oncology loses its signiﬁcance). High ICER
values discourage authors from publishing ICURs. These two
models are in fact quite similar because in oncology one can
expect high ratios of cost-effectiveness in the ﬁrst place. The
limitation of this part of the analysis is a small sample size
(ICURs are usually presented and so there are only a few 0 values
in the explanatory variable).
Analogously, we constructed a model explaining the publica-
tion of the ICER, which is also presented in Table 3. Using the
ICER is more frequent among models with a longer time horizon
(however, a longer time horizon is associated with higher values
of ICERs, when both ratios are reported). This may be because in
lifelong models it is natural to present cost-effectiveness meas-
ures stemming solely from life expectancy. The reporting of the
ICER is also more popular in oncology (ICURs are less favorable
there). ICURs exceeding the 100,000 PLN thresholds did not
additionally enhance the odds to present the ICER. No interaction
terms were statistically signiﬁcant.
In addition, we performed a logistic regression analysis
including the precision of estimation as an explanatory variable
to determine how the uncertainty of estimation affected the
decision on ICER/ICUR reporting. Table 4 presents the ﬁnal
results. We experimented with various deﬁnitions of precision
of estimation, with the one included in the table found to be the
most signiﬁcant. The sign of this association is reverted between
models; for example, the large uncertainty related to the ICER is
associated with the ICUR also being calculated and the large
uncertainty of the ICUR leads to less frequent reporting of
the ICER.
Including the precision of estimates resulted in the time
horizon of the analysis to be a statistically signiﬁcant predictor
of presenting both the ICER and the ICUR. The longer the time
horizon, the greater (lower) the probability of presenting the ICER
(ICUR).Precision of the Assessment of the ICER and the ICUR
We observed a high level of uncertainty of ratio assessment in
sensitivity analyses. In 32 of 80 (40%) and 133 of 297 (45%) cases,
ICERmax and ICURmax, respectively, were above the threshold of
100,000 PLN, whereas their corresponding ICERmin and ICURmin
were below. Thus, in almost 50% of the cases, a decision maker
may feel unsure about the base scenario result and may prefer to
ignore the results, focusing on other types of analyses presented
in HTA reports.
In most of the cases, the ICER is assessed with greater
uncertainty (see Fig. 3 in Supplemental Materials found at
http://dx.doi.org/10.1016/j.vhri.2014.06.008). For example, on aver-
age, the error deﬁned by Equation 1 is larger for the ICER than for
the ICUR by 4.7 degrees (t test paired, P* o 0.0001). Similar results
are obtained for errors deﬁned by Equations 2 and 3. Obviously,
errors for ICER and ICUR are correlated; for example, Pearson
correlation coefﬁcient for error type 1 amounts to 0.9638 and is
even greater for error 2 and error 3.
We tried to identify situations in which the ICUR is estimated
with greater error (Table 5). No interactions were statistically
signiﬁcant. In time ICUR errors are getting relatively smaller as
compared to ICER errors. In oncology, uncertainty related to the
ICUR is also smaller.
The second observation may be explained by the fact that low
HRQOL in such diseases reduces the impact of uncertainty
associated with the effect of treatment on life prolongation,
while the uncertainty related to the HRQOL estimation is less
meaningful due to short life expectancy. More formally, because
ΔQALY E ΔLYG  HRQOL þ life expectancy  ΔHRQOL, the
uncertainty of ΔQALY is small, as the uncertainty of ΔLYG is
multiplied by low HRQOL and the uncertainty of ΔHRQOL is
multiplied by low life expectancy.
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Although CUA still raises some controversies and is more
resource- and time-consuming than CEA, it is often recom-
mended in national guidelines as a ﬁrst-choice analysis. We
collected all the ICERs and ICURs that satisﬁed our inclusion
criteria from manufacturers’ submissions to AHTAPol and ana-
lyzed their values, precision of estimation, and factors associated
with their presentation.
We ﬁnd the following facts to be the most interesting. First,
even though HRQOL in general provides additional mechanism
transmitting treatment beneﬁts, it does not increase cost-
effectiveness in Poland (ICURs are usually higher, Fig. 1). The
reason is that including HRQOL also decreases the beneﬁts of life
prolongation due to possibly lower baseline utility and possible
improvements in the HRQOL do not moderate this effect. This is
the case especially in oncological diseases (Table 2), which is
quite intuitive accounting for the low utility of life.
As time passes CUAs tend to be less favorable than
CEAs (Table 2). Because of the short time horizon of our study,
it results not from a change in the health technologies assessed
(i.e., decreasing possibility to improve HRQOL by newly developed
drugs). More probably, as authors are increasingly expected to
perform CUA, it is also performed and reported in situations in
which it is not favorable. This is conﬁrmed by the analysis of
ICUR reporting (Table 3)—ICURs are being reported very often and
this trend was increasing in the analyzed time frame. This
tendency observed in the period 2007 to 2011 came ahead of
the new Reimbursement Act demanding the ICUR whenever
possible. The new act also demands a systematic review of utility
values to be used in economic analyses. This may strengthen the
above tendency of ICURs becoming less favorable and would call
for a dedicated study when new data have been gathered. These
observations, however, may be biased by the fact that ICERs are
not always presented.
Second, there are patterns regarding ICER/ICUR reporting.
Because ICURs are usually less favorable, it is not surprising that
when the ICER is above the threshold, ICURs are less frequently
reported (Table 3, the alternative model). One possible interpre-
tation might be that in case of unfavorable results, researches do
not bother collecting utility data and preparing a cost-utility
model that is most probably not going to change the overall
conclusion (or they do bother, but do not present additional,
unfavorable results). ICURs are less frequently shown in oncol-
ogy, whereas for ICERs it is vice versa (Table 3), which may be
considered a bias because ICURs are less favorable in oncology
(cf. Table 2; similar ﬁndings presented by Tengs [18] and Green-
berg and Neumann [19]). However, the long time horizon of an
analysis promotes presenting ICERs (Table 3), which is less
favorable then (Table 2). Perhaps in lifelong models LYGs are a
natural measure of an effect. This also shows that including
HRQOL in the model has a larger positive effect on the cost-
effectiveness of an assessed technology for longer time horizons
because there is time for improvements in utility to accumulate.
It is difﬁcult to interpret the impact of the ICER (ICUR)
precision of estimate on reporting the ICUR (ICER). Greater
precision in ICER estimation reduces the probability of ICUR
reporting, whereas greater precision in ICUR estimation increases
the probability of ICER reporting (Table 4). Because the ICUR is
omitted in only a few cases, one possible interpretation is that
whenever authors do not bother with presenting the ICUR, they
also do not perform a very thorough sensitivity analysis, thus
reducing the range for ICER values presented. The negative
association between ICUR estimation error and the ICER being
reported is more difﬁcult to interpret. Perhaps when the CUA is
performed and equipped with extensive sensitivity analysistriggering large uncertainty, authors do not bother with present-
ing the results of simple CEA.
Third, even though estimating the ICUR requires additional
parameters in the model, the resulting uncertainty is smaller.
Perhaps there is a large uncertainty regarding the life expectancy
that is reduced in the CUA by multiplying it by health states
utility, while the additional uncertainty stemming from HRQOL
estimation is smaller than this reduction. This is supported by
the fact that ICURs are relatively more precisely estimated in
oncology (Table 5). This ﬁnding is more robust to the limitations
of our study (i.e., publication bias) because ICURs are available in
most of the comparisons, and we would not expect authors to
omit the ICER when the related uncertainty is small. ICURs are
getting relatively more and more precisely estimated in time
(Table 5). The strong preference for the ICUR instead of the ICER
enforced in Poland might however change the situation because
ICURs would also have to be calculated in situations in which it is
difﬁcult to credibly assess the HRQOL or its changes.
Interestingly, in case of our data set, the conclusions are quite
different from those of Chapman et al. [17] (see Table 6 in
Supplemental Materials found at http://dx.doi.org/10.1016/j.vhri.
2014.06.008). In the study by Chapman et al., ICURs were usually
more favorable than ICERs. This is a qualitative difference from
our study. The most plausible explanation is the lack of ICUR
reporting bias in Poland, leading to a frequent publishing of
nonfavorable ones. There are also qualitative differences regard-
ing the relative values of ICERs and ICURs (that are reversed in
our study than in the study by Chapman et al.), but that is not
that important in our opinion because the mean values may be
driven by individual very high values (large asymmetry in both
our and Chapman et al.’s data set).
Because the aim of economic evaluations is to support the
decision making in health care, one of the most important
conclusions is that in the case of Chapman only 8% of paired
ratios were on the opposite sides of the threshold, affecting the
resource allocation decision, whereas in case of Polish data it is
13%. Although the numbers are not that different, we would say
that this percentage is signiﬁcant because it emphasizes how
important it is to select the right approach. As we collected
minimum and maximum values in sensitivity analyses, we
additionally noticed that in almost 50% of the cases the extreme
values were on the opposite sides of the WTP threshold, which
forces a decision maker to decide whether to adopt a conserva-
tive approach or a base-case scenario.
One important limitation of our study is the lack of possibility
to observe the values that are omitted by the authors of the
submissions. It is therefore difﬁcult to discover the true data-
generating process, that is, the process that led, for example, to
ICER omission. Currently, according to the new Reimbursement
Act, AHTAPol requires companies to also submit the imple-
mented model that allows to redo all the calculations and change
basic parameters. This means that it will be in principle possible
to add CEA to submitted CUA (e.g., by substituting trivial utility
values).
In conclusion, the above analysis is not to say that ICURs
should be preferred over ICERs in the HTA process or vice versa.
The decision should rather be based on economic arguments
regarding which parameter describes decision makers’ preferen-
ces more closely (and that reasoning would most likely point to
ICURs). We can, however, say that CUA had been very popular in
Poland before the new regulation came into force and that
regulation actually sanctioned HTA practice. No clear signals of
biases (selective reporting of the ICUR or the ICER) can be seen in
the data (though the data-generating process remains hidden
because of the limitations mentioned above). Thus, the regula-
tion was not actually needed in Poland. Still, it is worth noting
that Poland is quite mature a market regarding the HTA process,
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less HTA-experienced countries, it might make sense to force
using CUA by law, but that would most likely make it more
difﬁcult for oncology-related technologies to prove cost-effective.
Reassuringly, introducing additional parameters into modeling
(utilities) does not seem to worsen the precision of the estimates.
Luckily then, it seems that we may not have to choose between
being “roughly right” or “precisely wrong” but may be a little bit
more precisely right in HTA with CUA.Acknowledgments
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